Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Lapatinib|DRUG: Trastuzumab
Sponsor: Spanish Breast Cancer Research Group
Collaborators: GlaxoSmithKline